27.10.2013 Views

ALEX Y. NIE (聂焰) - Foley & Lardner LLP

ALEX Y. NIE (聂焰) - Foley & Lardner LLP

ALEX Y. NIE (聂焰) - Foley & Lardner LLP

SHOW MORE
SHOW LESS

Create successful ePaper yourself

Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.

ASSOCIATE<br />

A<strong>NIE</strong>@FOLEY.COM<br />

975 PAGE MILL ROAD<br />

PALO ALTO, CA 94304-1013<br />

(650) 251-1124<br />

<strong>ALEX</strong> Y. <strong>NIE</strong> (聂焰)<br />

聂焰博士,美国富理达律师事务所律师,是该所化学、生物技<br />

术和制药执业组,电子学执业组,和生命科学工业团队的成<br />

员。<br />

聂博士的事务包括专利申请以及相关的法律咨询。他的主要技<br />

术领域包括生命科学技术以及信息产业。<br />

在生命科学方面,除了传统的生物技术和化学制药以外,聂博<br />

士的执业重点也特别包括个性化医疗,生物和化学信息学,体<br />

外诊断和干细胞技术。<br />

在信息产业方面,聂博士的职业包括普通的软件和硬件技术,<br />

比如那些涉及到人工智能,机器学习,数据加密,移动平台,<br />

和数字电路设计。<br />

聂博士同时也是富理达律师事务所的中国开拓组队成员。他撰<br />

写了一些关于中国新专利法的文章,并且被邀请在由中国国务<br />

院法制办和美国商务部 2009 年在洛杉矶组织的中美法制交流<br />

会上演讲探讨了中国的专利执法现状。他的演讲内容随即被美<br />

国之音引用和报道。聂博士还于 2009 年代表加州再生医学研<br />

究院和中国科技部商定签署了合作意向书。<br />

在从事法律行业以前,聂博士曾是美国强生公司的强生药物研<br />

发有限公司的资深研究员。聂博士在强生公司的七年的研究方<br />

向是寻找签订用来评估小分子药物安全性的新型技术手段。他<br />

同时也是强生公司在关键途径研究所的代表。关键途径研究所<br />

是一个由美国食品和药物管理局(FDA)组织协调的,世界制<br />

药行业的跨公司的合作机构。其成立目标是验证新的科技手段<br />

来达到改进药物的审批过程。聂博士也参与了强生公司的中国<br />

行动计划,在其中帮助强生公司考评一些中国公司的技术能<br />

力。<br />

聂博士在 1993 年获得武汉大学生物化学学士的学位,然后在<br />

1996 年获得中国科技大学分子生物学的硕士学位。此后他留<br />

学美国并在 2001 年获得罗格斯大学生物化学博士和计算机科<br />

学硕士两个学位。2008 年,聂博士再次获得美国罗格斯大学<br />

纽瓦克法学院的法律博士学位。<br />

聂博士发表了 25 篇同行审查的科学论文,也在两本科学书籍<br />

©2011 <strong>Foley</strong> & <strong>Lardner</strong> <strong>LLP</strong> • Attorney Advertisement • Prior results do not guarantee a similar outcome • 321 North Clark Street, Chicago, IL 60654 • 312.832.4500


中著写章节。他曾被授予过美国健康研究院(NIH)的研究基金<br />

并在多个科学组织担任委员会成员。这些组织包括国际生命科<br />

学组织属下的健康和环境科学研究所,关键途径研究所,和<br />

FDA 的药物基因组数据标准委员会。聂博士曾被邀请担任<br />

2006 年在法国巴黎召开的药物信息协会年会的分会的主席并<br />

发表演讲。<br />

聂博士是美国加州的注册律师,并持有美国专利和商标局的注<br />

册执照。<br />

聂博士的代表论文:<br />

Nie, “USPTO’s 2010 – 2015 Strategic Plan (中文<br />

版标题:美国专利商标局的 2010-2015 战略规划),”<br />

published in <strong>Foley</strong> & <strong>Lardner</strong> <strong>LLP</strong> Fall 2010 edition<br />

of Legal News: China Quarterly Newsletter, Eye on<br />

China (October 2010)<br />

Best, Carsten and Nie, "Ninth Circuit," Ch. 10 in<br />

Patent Obviousness in the Wake of KSR International<br />

Co. v. Teleflex Inc., (Paul. M. Rivard and Alan<br />

Gardner, eds., 2010)<br />

Wright Bonnilla, Brinckerhoff, Konski and Nie,<br />

"Patent Eligibility of Personalized Medicine<br />

Method Claims Confirmed by Federal Circuit in<br />

Prometheus Labs., Inc. v. Mayo," published in<br />

<strong>Foley</strong> & <strong>Lardner</strong> <strong>LLP</strong> Legal News Alert: Biotechnology<br />

& Pharmaceutical (September 2009)<br />

Konski, Brinckenhoff and Nie, "Genes Under the<br />

Microscope – Novel or Not?" published in<br />

Intellectual Property Today (July 2009)<br />

Nie, "Introduction to the U.S. Patent Reform Act<br />

of 2009(中文版标题:2009 年美国专利改革法案介<br />

绍)," published in <strong>Foley</strong> & <strong>Lardner</strong> <strong>LLP</strong> Summer<br />

2009 Eye on China Newsletter (August 2009)<br />

Zhao, Nie and Tang, "PRC Supreme People’s<br />

Court Patent Infringement Enforcement Guidance:<br />

The "Draft" Published for Comments by the Patent<br />

Community," published in <strong>Foley</strong> & <strong>Lardner</strong> <strong>LLP</strong><br />

Legal News Alert: China (July 2009)<br />

Fielden and Nie et al., "Interlaboratory evaluation<br />

of genomic signatures for predicting<br />

carcinogenicity in the rat," published in<br />

Toxicological Sciences (vol 103, pages 28-34,<br />

2008)<br />

©2011 <strong>Foley</strong> & <strong>Lardner</strong> <strong>LLP</strong> • Attorney Advertisement • Prior results do not guarantee a similar outcome • 321 North Clark Street, Chicago, IL 60654 • 312.832.4500


Nie et al., "Predictive Toxicogenomics Approaches<br />

Reveal Underlying Molecular Mechanisms of<br />

Nongenotoxic Carcinogenicity," published in<br />

Molecular Carcinogenesis (vol 45, pages 914-933,<br />

2006)<br />

Nie, McMillian and Lord, "Toxicogenomics in Drug<br />

Safety Evaluation: Bridging Drug Discovery and<br />

Development," published in Carmen and<br />

Hardiman eds. Biochips as Pathways to Drug<br />

Discovery. Florida: Taylor & Francis Group (pages<br />

69-96, 2006)<br />

代表讲座和简报:<br />

"U.S. Perspective of Patent Enforcement in China,"<br />

2009 U.S.-China Legal Exchange, Los Angeles,<br />

California (October 12, 2009)<br />

"An Analysis of the Characteristics of Licensed<br />

Clean Tech Patents from Publicly Announced<br />

Commercialization Deals," the 5th International<br />

Congress of Nano-Bio Clean Tech 2008<br />

conference, San Francisco, California (October<br />

27-30, 2008)<br />

"Preparing the Critical Path to Acceptance of<br />

Toxicogenomic Data in Drug Safety Evaluation,"<br />

the 2007 Joint Statistics Meeting, Salt Lake City,<br />

Utah (July 26 – August 2, 2007)<br />

"Bioinformatics Lighting a New Path to Better<br />

Drug Development," the Drug Information<br />

Association 18th Annual EuroMeeting, Paris,<br />

France (March 6-8, 2006)<br />

©2011 <strong>Foley</strong> & <strong>Lardner</strong> <strong>LLP</strong> • Attorney Advertisement • Prior results do not guarantee a similar outcome • 321 North Clark Street, Chicago, IL 60654 • 312.832.4500

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!